


Asymmetric dimethylarginine-d7 hydrochloride hydrate

Cat. No.:	HY-113216S
Target:	Endogenous Metabolite; NO Synthase
Pathway:	Metabolic Enzyme/Protease; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



HCl xH₂O

BIOLOGICAL ACTIVITY

Description	Asymmetric dimethylarginine-d7 hydrochloride hydrate is the deuterium labeled Asymmetric dimethylarginine. Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS), and functions as a marker of endothelial dysfunction in a num
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019 Feb;53(2):211-216.
- [2]. Hudson CL, et al. The cardiovascular risk marker asymmetric dimethylarginine is elevated in asymptomatic, untreated HIV-1 infection and correlates with markers of immune activation and disease progression. *Ann Clin Biochem.* 2014 Sep;51(Pt 5):568-75.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA